Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 2/2016

01-02-2016 | Leading Article

Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date

Authors: Mary R. Lee, Matthew C. H. Rohn, Gianluigi Tanda, Lorenzo Leggio

Published in: CNS Drugs | Issue 2/2016

Login to get access

Abstract

The neuropeptide oxytocin plays a role in reward, stress, social affiliation, learning, and memory processes. As such, there is increasing interest in oxytocin as a potential treatment for addictions. The endogenous oxytocin system is itself altered by short- or long-term exposure to drugs of abuse. A large number of preclinical studies in rodents have investigated the effect of oxytocin administration on various drug-induced behaviors to determine whether oxytocin can reverse the neuroadaptations occurring with repeated drug and alcohol use. In addition, the mechanisms by which oxytocin acts to modify the behavioral response to drugs of abuse are beginning to be understood. More recently, a few small clinical studies have been conducted in cocaine, cannabis, and alcohol dependence. This review summarizes the preclinical as well as clinical literature to date on the oxytocin system and its relevance to drug and alcohol addiction.
Literature
1.
Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12(9):524–38.CrossRefPubMed
2.
Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006;7(2):126–36.CrossRefPubMed
3.
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–83.PubMed
4.
Stoop R. Neuromodulation by oxytocin and vasopressin in the central nervous system as a basis for their rapid behavioral effects. Curr Opin Neurobiol. 2014;29:187–93.CrossRefPubMed
5.
Pinol RA, Bateman R, Mendelowitz D. Optogenetic approaches to characterize the long-range synaptic pathways from the hypothalamus to brain stem autonomic nuclei. J Neurosci Methods. 2012;210(2):238–46.CrossRefPubMedPubMedCentral
6.
Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol. 2009;30(4):534–47.CrossRefPubMedPubMedCentral
7.
Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology. 2013;38(10):1985–93.CrossRefPubMed
8.
Beets I, Janssen T, Meelkop E, Temmerman L, Suetens N, Rademakers S, et al. Vasopressin/oxytocin-related signaling regulates gustatory associative learning in C. elegans. Science. 2012;338(6106):543–5.CrossRefPubMed
9.
Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature. 1992;356(6369):526–9.CrossRefPubMed
10.
Lee HJ, Macbeth AH, Pagani JH, Young WS 3rd. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88(2):127–51.PubMedPubMedCentral
11.
Smith AL, Freeman SM, Stehouwer JS, Inoue K, Voll RJ, Young LJ, et al. Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors. Bioorg Med Chem. 2012;20(8):2721–38.CrossRefPubMedPubMedCentral
12.
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473–512.CrossRefPubMed
13.
Pedersen CA, Ascher JA, Monroe YL, Prange AJ Jr. Oxytocin induces maternal behavior in virgin female rats. Science. 1982;216(4546):648–50.CrossRefPubMed
14.
Pedersen CA, Prange AJ Jr. Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci USA. 1979;76(12):6661–5.CrossRefPubMedPubMedCentral
15.
Williams JR, Insel TR, Harbaugh CR, Carter CS. Oxytocin administered centrally facilitates formation of a partner preference in female prairie voles (Microtus ochrogaster). J Neuroendocrinol. 1994;6(3):247–50.CrossRefPubMed
16.
Insel TR, Shapiro LE. Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles. Proc Natl Acad Sci USA. 1992;89(13):5981–5.CrossRefPubMedPubMedCentral
17.
Liu Y, Wang ZX. Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuroscience. 2003;121(3):537–44.CrossRefPubMed
18.
Melis MR, Melis T, Cocco C, Succu S, Sanna F, Pillolla G, et al. Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats. Eur J Neurosci. 2007;26(4):1026–35.CrossRefPubMed
19.
Wei D, Lee D, Cox CD, Karsten CA, Penagarikano O, Geschwind DH, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci USA. 2015;112(45):14084–9.CrossRefPubMed
20.
Tracy LM, Georgiou-Karistianis N, Gibson SJ, Giummarra MJ. Oxytocin and the modulation of pain experience: implications for chronic pain management. Neurosci Biobehav Rev. 2015;55:53–67.CrossRefPubMed
21.
Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012;73(3):553–66.CrossRefPubMed
22.
Arletti R, Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987;41(14):1725–30.CrossRefPubMed
23.
Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci. 2009;29(7):2259–71.CrossRefPubMed
24.
Burkett JP, Young LJ. The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. Psychopharmacology. 2012;224(1):1–26.CrossRefPubMedPubMedCentral
25.
Liu Y, Young KA, Curtis JT, Aragona BJ, Wang Z. Social bonding decreases the rewarding properties of amphetamine through a dopamine D1 receptor-mediated mechanism. J Neurosci. 2011;31(22):7960–6.CrossRefPubMedPubMedCentral
26.
Liu Y, Aragona BJ, Young KA, Dietz DM, Kabbaj M, Mazei-Robison M, et al. Nucleus accumbens dopamine mediates amphetamine-induced impairment of social bonding in a monogamous rodent species. Proc Natl Acad Sci USA. 2010;107(3):1217–22.CrossRefPubMedPubMedCentral
27.
Hostetler CM, Ryabinin AE. Social partners prevent alcohol relapse behavior in prairie voles. Psychoneuroendocrinology. 2014;39:152–7.CrossRefPubMed
28.
Anacker AM, Ahern TH, Hostetler CM, Dufour BD, Smith ML, Cocking DL, et al. Drinking alcohol has sex-dependent effects on pair bond formation in prairie voles. Proc Natl Acad Sci USA. 2014;111(16):6052–7.CrossRefPubMedPubMedCentral
29.
McCullough ME, Churchland PS, Mendez AJ. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev. 2013;37(8):1485–92.CrossRefPubMed
30.
Johns JM, Caldwell JD, Pedersen CA. Acute cocaine treatment decreases oxytocin levels in the rat hippocampus. Neuropeptides. 1993;24(3):165–9.CrossRefPubMed
31.
Meyers RA, Zavala AR, Neisewander JL. Dorsal, but not ventral, hippocampal lesions disrupt cocaine place conditioning. Neuroreport. 2003;14(16):2127–31.CrossRefPubMed
32.
Sarnyai Z, Kovacs GL. Role of oxytocin in the neuroadaptation to drugs of abuse. Psychoneuroendocrinology. 1994;19(1):85–117.CrossRefPubMed
33.
Georgiou P, Zanos P, Ehteramyan M, Hourani S, Kitchen I, Maldonado R, et al. Differential regulation of mGlu5 R and MuOPr by priming- and cue-induced reinstatement of cocaine-seeking behaviour in mice. Addict Biol. 2015;20(5):902–12.CrossRefPubMed
34.
Zanos P, Wright SR, Georgiou P, Yoo JH, Ledent C, Hourani SM, et al. Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism. Pharmacol Biochem Behav. 2014;119:72–9.CrossRefPubMed
35.
Light KC, Grewen KM, Amico JA, Boccia M, Brownley KA, Johns JM. Deficits in plasma oxytocin responses and increased negative affect, stress, and blood pressure in mothers with cocaine exposure during pregnancy. Addict Behav. 2004;29(8):1541–64.CrossRefPubMedPubMedCentral
36.
You ZD, Li JH, Song CY, Wang CH, Lu CL. Chronic morphine treatment inhibits oxytocin synthesis in rats. Neuroreport. 2000;11(14):3113–6.CrossRefPubMed
37.
Zanos P, Georgiou P, Wright SR, Hourani SM, Kitchen I, Winsky-Sommerer R, et al. The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. Neuropsychopharmacology. 2014;39(4):855–65.CrossRefPubMedPubMedCentral
38.
Lynn JM. Intravenous alcohol infusion for premature labor. J Am Osteopath Assoc. 1970;70(2):167–70.PubMed
39.
Marchesi C, Chiodera P, Brusamonti E, Volpi R, Coiro V. Abnormal plasma oxytocin and beta-endorphin levels in alcoholics after short and long term abstinence. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(5):797–807.CrossRefPubMed
40.
Sivukhina EV, Dolzhikov AA, Morozov IuE, Jirikowski GF, Grinevich V. Effects of chronic alcoholic disease on magnocellular and parvocellular hypothalamic neurons in men. Horm Metab Res. 2006;38(6):382–90.CrossRefPubMed
41.
Butovsky E, Juknat A, Elbaz J, Shabat-Simon M, Eilam R, Zangen A, et al. Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci. 2006;31(4):795–804.CrossRefPubMed
42.
Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4(4):359–66.CrossRefPubMed
43.
Broadbear JH, Tunstall B, Beringer K. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) using a drug discrimination paradigm in the rat. Addict Biol. 2011;16(2):202–14.CrossRefPubMed
44.
van Nieuwenhuijzen PS, Long LE, Hunt GE, Arnold JC, McGregor IS. Residual social, memory and oxytocin-related changes in rats following repeated exposure to gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology. 2010;212(4):663–74.CrossRefPubMed
45.
Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE, et al. Addiction as a stress surfeit disorder. Neuropharmacology. 2014;76(Pt B):370–82.
46.
Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther. 2008;14(3):165–70.CrossRefPubMed
47.
Taylor SE, Saphire-Bernstein S, Seeman TE. Are plasma oxytocin in women and plasma vasopressin in men biomarkers of distressed pair-bond relationships? Psychol Sci. 2010;21(1):3–7.CrossRefPubMed
48.
Bohus B, Kovacs GL, de Wied D. Oxytocin, vasopressin and memory: opposite effects on consolidation and retrieval processes. Brain Res. 1978;157(2):414–7.CrossRefPubMed
49.
Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology. 2010;58(1):38–43.CrossRefPubMed
50.
Carson DS, Hunt GE, Guastella AJ, Barber L, Cornish JL, Arnold JC, et al. Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addict Biol. 2010;15(4):448–63.CrossRefPubMed
51.
Qi J, Yang JY, Song M, Li Y, Wang F, Wu CF. Inhibition by oxytocin of methamphetamine-induced hyperactivity related to dopamine turnover in the mesolimbic region in mice. Naunyn Schmiedebergs Arch Pharmacol. 2008;376(6):441–8.CrossRefPubMed
52.
Qi J, Yang JY, Wang F, Zhao YN, Song M, Wu CF. Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology. 2009;56(5):856–65.CrossRefPubMed
53.
54.
Baracz SJ, Cornish JL. Oxytocin modulates dopamine-mediated reward in the rat subthalamic nucleus. Horm Behav. 2013;63(2):370–5.CrossRefPubMed
55.
Baracz SJ, Rourke PI, Pardey MC, Hunt GE, McGregor IS, Cornish JL. Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behav Brain Res. 2012;228(1):185–93.CrossRefPubMed
56.
Han WY, Du P, Fu SY, Wang F, Song M, Wu CF, et al. Oxytocin via its receptor affects restraint stress-induced methamphetamine CPP reinstatement in mice: involvement of the medial prefrontal cortex and dorsal hippocampus glutamatergic system. Pharmacol Biochem Behav. 2014;119:80–7.CrossRefPubMed
57.
Manbeck KE, Shelley D, Schmidt CE, Harris AC. Effects of oxytocin on nicotine withdrawal in rats. Pharmacol Biochem Behav. 2014;116:84–9.CrossRefPubMed
58.
Kovacs GL, Sarnyai Z, Izbeki F, Szabo G, Telegdy G, Barth T, et al. Effects of oxytocin-related peptides on acute morphine tolerance: opposite actions by oxytocin and its receptor antagonists. J Pharmacol Exp Ther. 1987;241(2):569–74.PubMed
59.
Kovacs GL, Izbeki F, Horvath Z, Telegdy G. Effects of oxytocin and a derivative (Z-prolyl-d-leucine) on morphine tolerance/withdrawal are mediated by the limbic system. Behav Brain Res. 1984;14(1):1–8.CrossRefPubMed
60.
Kovacs GL, Horvath Z, Sarnyai Z, Faludi M, Telegdy G. Oxytocin and a C-terminal derivative (Z-prolyl-d-leucine) attenuate tolerance to and dependence on morphine and interact with dopaminergic neurotransmission in the mouse brain. Neuropharmacology. 1985;24(5):413–9.CrossRefPubMed
61.
Sarnyai Z, Viski S, Krivan M, Szabo G, Kovacs GL, Telegdy G. Endogenous oxytocin inhibits morphine tolerance through limbic forebrain oxytocin receptors. Brain Res. 1988;463(2):284–8.CrossRefPubMed
62.
Kovacs GL, Faludi M, Telegdy G. Oxytocin diminishes heroin tolerance in mice. Psychopharmacology. 1985;86(3):377–9.CrossRefPubMed
63.
Kovacs GL, Borthaiser Z, Telegdy G. Oxytocin reduces intravenous heroin self-administration in heroin-tolerant rats. Life Sci. 1985;37(1):17–26.CrossRefPubMed
64.
Ibragimov R, Kovacs GL, Szabo G, Telegdy G. Microinjection of oxytocin into limbic-mesolimbic brain structures disrupts heroin self-administration behavior: a receptor-mediated event? Life Sci. 1987;41(10):1265–71.CrossRefPubMed
65.
Moaddab M, Hyland BI, Brown CH. Oxytocin enhances the expression of morphine-induced conditioned place preference in rats. Psychoneuroendocrinology. 2015;53:159–69.CrossRefPubMed
66.
Bicknell RJ, Leng G, Lincoln DW, Russell JA. Naloxone excites oxytocin neurones in the supraoptic nucleus of lactating rats after chronic morphine treatment. J Physiol. 1988;396:297–317.CrossRefPubMedPubMedCentral
67.
Sarnyai Z, Szabo G, Kovacs GL, Telegdy G. Opposite actions of oxytocin and vasopressin in the development of cocaine-induced behavioral sensitization in mice. Pharmacol Biochem Behav. 1992;43(2):491–4.CrossRefPubMed
68.
Sarnyai Z, Biro E, Babarczy E, Vecsernyes M, Laczi F, Szabo G, et al. Oxytocin modulates behavioural adaptation to repeated treatment with cocaine in rats. Neuropharmacology. 1992;31(6):593–8.CrossRefPubMed
69.
Kovacs GL, Sarnyai Z, Barbarczi E, Szabo G, Telegdy G. The role of oxytocin-dopamine interactions in cocaine-induced locomotor hyperactivity. Neuropharmacology. 1990;29(4):365–8.CrossRefPubMed
70.
Sarnyai Z, Szabo G, Kovacs GL, Telegdy G. Oxytocin attenuates the cocaine-induced exploratory hyperactivity in mice. Neuroreport. 1990;1(3–4):200–2.CrossRefPubMed
71.
Sarnyai Z, Babarczy E, Krivan M, Szabo G, Kovacs GL, Barth T, et al. Selective attenuation of cocaine-induced stereotyped behaviour by oxytocin: putative role of basal forebrain target sites. Neuropeptides. 1991;19(1):51–6.CrossRefPubMed
72.
De Groot AN, Vree TB, Hekster YA, Pesman GJ, Sweep FC, Van Dongen PJ, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol. 1995;47(7):571–5.CrossRefPubMed
73.
Mens WB, Witter A, van Wimersma Greidanus TB. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res. 1983;262(1):143–9.CrossRefPubMed
74.
Zhou L, Sun WL, Young AB, Lee K, McGinty JF, See RE. Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function. Int J Neuropsychopharmacol. 2014. doi:10.​1093/​ijnp/​pyu009 (Epub 2014 Oct 31).
75.
Qi J, Han WY, Yang JY, Wang LH, Dong YX, Wang F, et al. Oxytocin regulates changes of extracellular glutamate and GABA levels induced by methamphetamine in the mouse brain. Addict Biol. 2012;17(4):758–69.CrossRefPubMed
76.
Morales-Rivera A, Hernandez-Burgos MM, Martinez-Rivera A, Perez-Colon J, Rivera R, Montalvo J, et al. Anxiolytic effects of oxytocin in cue-induced cocaine seeking behavior in rats. Psychopharmacology. 2014;231(21):4145–55.CrossRefPubMed
77.
Baracz SJ, Everett NA, Cornish JL. The involvement of oxytocin in the subthalamic nucleus on relapse to methamphetamine-seeking behaviour. PloS One. 2015;10(8):e0136132.CrossRefPubMedPubMedCentral
78.
Baracz SJ, Everett NA, McGregor IS, Cornish JL. Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine-seeking behaviour in rats. Addict Biol. 2014. doi:10.​1111/​adb.​12198
79.
Bowen MT, Peters ST, Absalom N, Chebib M, Neumann ID, McGregor IS. Oxytocin prevents ethanol actions at delta subunit-containing GABAA receptors and attenuates ethanol-induced motor impairment in rats. Proc Natl Acad Sci USA. 2015;112(10):3104–9.CrossRefPubMedPubMedCentral
80.
Szabo G, Kovacs GL, Szekeli S, Telegdy G. The effects of neurohypophyseal hormones on tolerance to the hypothermic effect of ethanol. Alcohol. 1985;2(4):567–74.CrossRefPubMed
81.
Szabo G, Kovacs GL, Telegdy G. Intraventricular administration of neurohypophyseal hormones interferes with the development of tolerance to ethanol. Acta Physiol Hung. 1989;73(1):97–103.PubMed
82.
Hoffman PL, Ritzmann RF, Walter R, Tabakoff B. Arginine vasopressin maintains ethanol tolerance. Nature. 1978;276(5688):614–6.CrossRefPubMed
83.
Szabo G, Kovacs GL, Telegdy G. Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal. Alcohol Alcohol. 1987;22(1):71–4.PubMed
84.
Peters S, Slattery DA, Flor PJ, Neumann ID, Reber SO. Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice. Addict Biol. 2013;18(1):66–77.CrossRefPubMed
85.
McGregor IS, Bowen MT. Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav. 2012;61(3):331–9.CrossRefPubMed
86.
87.
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002;5(6):514–6.CrossRefPubMed
88.
Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep. 2013;3:3440.CrossRefPubMedPubMedCentral
89.
Dal Monte O, Noble PL, Turchi J, Cummins A, Averbeck BB. CSF and blood oxytocin concentration changes following intranasal delivery in macaque. PloS One. 2014;9(8):e103677.
90.
Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov-Polevoi A, et al. Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res. 2013;37(3):484–9.CrossRefPubMedPubMedCentral
91.
McRae-Clark AL, Baker NL, Maria MM, Brady KT. Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology. 2013;228(4):623–31.CrossRefPubMedPubMedCentral
92.
Flanagan JC, Baker NL, McRae-Clark AL, Brady KT, Moran-Santa Maria MM. Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence. Psychiatry Res. 2015;229(1–2):94–100.CrossRefPubMed
93.
Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H. Effects of MDMA and Intranasal oxytocin on social and emotional processing. Neuropsychopharmacology. 2014;39(7):1654–63.CrossRefPubMedPubMedCentral
94.
Lee MR, Glassman M, King-Casas B, Kelly DL, Stein EA, Schroeder J, et al. Complexity of oxytocins effects in a chronic cocaine dependent population. Eur Neuropsychopharmacol. 2014;24(9):1483–91.CrossRefPubMed
95.
96.
Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583–8.CrossRefPubMed
97.
Liberzon I, Trujillo KA, Akil H, Young EA. Motivational properties of oxytocin in the conditioned place preference paradigm. Neuropsychopharmacology. 1997;17(6):353–9.CrossRefPubMed
98.
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114–26.CrossRefPubMed
99.
Laszlo K, Kovacs A, Zagoracz O, Ollmann T, Peczely L, Kertes E, et al. Positive reinforcing effect of oxytocin microinjection in the rat central nucleus of amygdala. Behav Brain Res. 2016;296:279–85.CrossRefPubMed
100.
Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003;54(12):1389–98.CrossRefPubMed
101.
Bowen MT, Carson DS, Spiro A, Arnold JC, McGregor IS. Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. PloS One. 2011;6(11):e27237.CrossRefPubMedPubMedCentral
102.
Hicks C, Cornish JL, Baracz SJ, Suraev A, McGregor IS. Adolescent pre-treatment with oxytocin protects against adult methamphetamine-seeking behavior in female rats. Addict Biol. 2014. doi:10.​1111/​adb.​12197
103.
Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci. 2004;24(12):2974–82.
104.
Ibragimov R, Kovacs G. Effect of oxytocin microinjections into the lateral septal nucleus on intravenous heroin self-administration in heroin-tolerant rats [in Russian]. Fiziologicheskii Zh SSSR Im I M Sechenova. 1987;73(12):1625–9.
105.
Tirelli E, Jodogne C, Legros JJ. Oxytocin blocks the environmentally conditioned compensatory response present after tolerance to ethanol-induced hypothermia in mice. Pharmacol Biochem Behav. 1992;43(4):1263–7.CrossRefPubMed
Metadata
Title
Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
Authors
Mary R. Lee
Matthew C. H. Rohn
Gianluigi Tanda
Lorenzo Leggio
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 2/2016
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-016-0313-z

Other articles of this Issue 2/2016

CNS Drugs 2/2016 Go to the issue

Review Article

Worldwide Differences in Regulations of Clozapine Use

Current Opinion

Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities

Review Article

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

Leading Article

Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia

Adis Drug Evaluation

Adjunctive Brexpiprazole: A Review in Major Depressive Disorder

Original Research Article

The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective